Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Bibliographic Details
Main Authors:	Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani, Pier Luigi Canonico
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2018-11-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	cost-effectiveness peginterferon beta-1a multiple sclerosis
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1385

Similar Items

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

[Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
by: Annette Kolb-Mäurer, et al.
Published: (2019-06-01)

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
by: Gianluca Furneri, et al.
Published: (2016-06-01)

Peginterferon Treatment In Children: A Review Of Chronic Hepatitis B And Chronic Hepatitis C Treatment
by: Makbule EREN
Published: (2009-11-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

[Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
by: Gianluca Furneri, et al.
Published: (2016-03-01)

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
by: Alejandro Soza, M.D., et al.
Published: (2015-01-01)

EVALUATION OF HBV DNA LEVELS IN SALIVA IN SUBJECTS WITH DIFFERENT VIREMIA AS WELL AS DURING PEGINTERFERON α-2a THERAPY.
by: Assya Krasteva, et al.
Published: (2013-08-01)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
by: Gianluca Furneri, et al.
Published: (2019-06-01)

[Pegylation and interferons in multiple sclerosis]
by: Diego Centonze, et al.
Published: (2016-07-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Peginterferon beta-1a – nowa postać interferonu beta-1a
by: Zdzisław Maciejek, et al.
Published: (2015-11-01)

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
by: Suh Yoon Yang, et al.
Published: (2015-06-01)

An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
by: Pavan Bhargava, et al.
Published: (2016-11-01)

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
by: Zhang Yu-guo, et al.
Published: (2011-06-01)

Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs
by: Xuli Bao, et al.
Published: (2020-07-01)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
by: Artico Simara, et al.
Published: (2012-12-01)

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
by: Oliver Findling, et al.
Published: (2018-08-01)

Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir
by: Vladimir Marquez-Azalgara, et al.
Published: (2014-09-01)

PEGINTERFERON-ALPHA 2A RELATED PERIPHERAL NEUROPATHY: A CASE REPORT AND REVIEW OF THE LITERATURE
by: Amalia Ghergu, et al.
Published: (2017-09-01)

Multiple Sclerosis Relapsing Remitting Progressive Type
by: Nora Fitri, et al.
Published: (2020-12-01)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
by: Seok Hoo Jeong, et al.
Published: (2012-12-01)

Sexual dysfunction in males with hepatitis C virus: Relevance to histopathologic changes and peginterferon treatment
by: Kamal A El-Atrebi, et al.
Published: (2011-01-01)

Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis
by: Izadora Nogueira Fonte Boa, et al.

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

[Pegylated interferon beta-1a on the Italian market]
by: Mario Eandi
Published: (2016-07-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
by: Radu Tanasescu, et al.
Published: (2014-04-01)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
by: Hendin B, et al.
Published: (2018-07-01)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
by: V. M. Alifirova, et al.
Published: (2010-08-01)

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
by: Nae-Yun Heo, et al.
Published: (2013-03-01)

Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies
by: Kay, Kathleen Alexandra
Published: (2016)

Multimodal evoked potential in monitoring activity relapsing and remitting multiple sclerosis
by: Poverennova I.E., et al.
Published: (2018-03-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Farmacovigilância no tratamento com peginterferon e ribavirina em pacientes com hepatite C crônica no serviço de hepatologia do Hospital Universitário de Aracaju-SE
by: Nogueira, José Barreto Cruz
Published: (2017)

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
by: Forooz Peiravian, et al.
Published: (2016-09-01)

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
by: Ming-Yen Hsieh, et al.
Published: (2012-02-01)